Assembly Biosciences (ASMB) Total Debt (2010 - 2011)

Assembly Biosciences' (ASMB) quarterly Total Debt came in at $1.3 million in Q2 2011, down 21.91% quarter-over-quarter from $1.7 million in Q4 2010.

Assembly Biosciences (ASMB) Total Debt (2010 - 2011) Analysis & Trends

Assembly Biosciences' Total Debt history runs 2 years deep, the most recent figure standing at $1.3 million for Q2 2011.

On a quarterly basis, Total Debt changed N/A year-over-year to $1.3 million in Q2 2011; TTM through Jun 2011 was $1.3 million, a N/A change from a year earlier, with the FY2010 full-year figure at $1.7 million, changed N/A from the prior year.
Total Debt retreated to $1.3 million in Q2 2011 per ASMB's latest filing, from $1.7 million in the prior quarter.
Across five years, Total Debt topped out at $1.7 million in Q4 2010 and bottomed at $1.3 million in Q2 2011.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	110.96 Mn
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	959.06 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Assembly Biosciences	431.63 Mn	205.03 Mn	-	-

Download Data

Date	Value
Jun 30, 2011	1.32 Mn
Dec 31, 2010	1.69 Mn